People · Operator
Named in public records as an officer, director or promoter · active 2016–2024 · Biotechnology, Pharmaceuticals, Medical Devices
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Marea Therapeutics, Inc. | — | Biotechnology | Series C | $65.4M | $595.3M | 2024 |
| AsclepiX Therapeutics, Inc. | — | Biotechnology | Series A | $28.0M | $83.4M | 2023 |
| Stream Biomedical, Inc. | — | Pharmaceuticals | Series B | $21.5M | $411.7M | 2021 |
| Vyome Therapeutics Inc. | — | Pharmaceuticals | Series A | $14.5M | $351.1M | 2018 |
| CereVasc, Inc. | — | Biotechnology | Series A | $11.1M | $399.6M | 2020 |
| Resolys Bio, Inc. | — | Biotechnology | Series A | $10.0M | $361.5M | 2016 |
| Juno Diagnostics, Inc. | — | Medical Devices | Series A | $6.3M | $107.8M | 2021 |
| PolyCore Therapeutics, Inc. | — | Biotechnology | Series A | $4.7M | $78.1M | 2022 |
Chris Garabedian at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Chris Garabedian on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Frederick Callori | 3 | 4 |
| Krishna Gupta | 1 | 9 |
| Patrick Sullivan | 1 | 7 |
| Aaron Royston | 1 | 7 |
| Maha Katabi | 1 | 6 |
| Steven Altschuler | 1 | 5 |
| Sapna Srivastava | 1 | 3 |
| Amir Shojaei | 1 | 3 |
| Mohanjit Jolly | 1 | 3 |
| Ben Askew | 1 | 3 |
| John McMichael | 1 | 2 |
| Joshua Barer | 1 | 2 |
| Jeffrey A. Eckmann | 1 | 2 |
| Jeff Tong | 1 | 2 |
| William Schwieterman | 1 | 2 |
| Jordan Green | 1 | 2 |
| Ted Love | 1 | 2 |
| Robert Dempsey | 1 | 2 |
| Josh Lehrer | 1 | 2 |
| Jordan J. Green | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.